Vol.

No.

October 31, 2025Oct 31, 2025

DOWNLOAD THE PDF

Cover Story

Cancer centers adapt to life without site visits as NIH changes CCSG review

Love them or hate them, site visits have been a part of the culture of NCI-designated cancer centers for decades, shaping the process for admitting members to the elite club and influencing internal politics within institutions.

Clinical

Class action complaint alleging GRAIL insider fraud resubmitted after dismissal

By Jacquelyn Cobb

Friends publishes three white papers ahead of annual meeting
Topics: Clinical trials on rare cancers, combination drug trials, multi-regional studies

By Sara Willa Ernst

Clinical Trials & Tribulations

How GLP-1RA drugs are reshaping patient physiology and the future of oncology

By Deborah Phippard

Cancer Policy

Paychecks stop for HHS workers as shutdown continues

NEJM, public health group to launch alternate publication to CDC’s MMWR

Senators, nonprofits respond to Trump’s avowed support for IVF

In Brief

Jonathan Licht named president, chief scientific officer at Van Andel Institute

UIC, UI Health, and Cook County Health expand partnership to strengthen healthcare safety net

Vinai Gondi, Bridget Koontz, Priya Rastogi, Lisa Lenrow named to NRG Oncology committee leadership

Eytan Ruppin named deputy director of Translational Research Institute at Cedars-Sinai

Kimberly Vanderhorst, Terri Lynn Dunn receive the Brown Foundation nursing award at MD Anderson

Northwell Cancer Institute, Cancer Hope Network offer joint peer support program

Clinical Roundup

Ozekibart improves PFS in chondrosarcoma, registrational phase II trial shows

Targeted radiation during surgery reduces pancreatic cancer recurrence, Hopkins study finds

Drugs approved for pain also reduce bone cancer growth, Hopkins-led pre-clinical study finds

Researchers develop technique to track chemotherapy drug inside cells

Shortened version of HER2 protein may drive treatment resistance in breast cancer, Mayo study finds

Enhancing the body’s “first responder” cells may boost immune therapy, Mayo study finds

Drugs & Targets

FDA publishes draft guidance to accelerate biosimilar development and lower costs

EC approves Keytruda combination for a head-and-neck indication

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues